P B. Vermeulen

Universiteit Antwerpen (Belgium) 
Oncology, Molecular Biology, Biostatistics Biology
"P Vermeulen"
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Billiet C, Joye I, Mercier C, et al. (2020) Outcome and toxicity of hypofractionated image-guided SABR for spinal oligometastases. Clinical and Translational Radiation Oncology. 24: 65-70
Barnhill R, van Dam PJ, Vermeulen P, et al. (2020) Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value. The Journal of Pathology. Clinical Research
Rypens C, Marsan M, Van Berckelaer C, et al. (2020) Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activity. Breast Cancer Research and Treatment
Bertucci F, Rypens C, Finetti P, et al. (2019) NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers. Molecular Oncology
Latacz E, Caspani E, Barnhill R, et al. (2019) Pathological features of vessel co-option versus sprouting angiogenesis. Angiogenesis
Mercier C, Dirix P, Ost P, et al. (2019) A phase III randomized-controlled, single-blind trial to improve quality of life with stereotactic body radiotherapy for patients with painful bone metastases (ROBOMET). Bmc Cancer. 19: 876
Kuczynski EA, Vermeulen PB, Pezzella F, et al. (2019) Vessel co-option in cancer. Nature Reviews. Clinical Oncology
Van Berckelaer C, Rypens C, van Dam P, et al. (2019) Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression. Breast Cancer Research : Bcr. 21: 28
Nik-Zainal S, Davies H, Staaf J, et al. (2019) Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature
Mercier C, Dirix P, Meijnders P, et al. (2018) A phase I dose-escalation trial of stereotactic ablative body radiotherapy for non-spine bone and lymph node metastases (DESTROY-trial). Radiation Oncology (London, England). 13: 152
See more...